The Relationship Between Reduction in Low-Density Lipoprotein Cholesterol by Statins and Reduction in Risk of Cardiovascular Outcomes: An Updated Meta-Analysis

被引:147
作者
Delahoy, Philippa J. [2 ]
Magliano, Dianna J. [1 ,3 ]
Webb, Kate [2 ]
Grobler, Mendel [2 ]
Liew, Danny [4 ]
机构
[1] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[2] Pfizer Australia Pty Ltd, W Ryde, Australia
[3] Baker IDI Heart & Diabet Inst, Caulfield, Australia
[4] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
关键词
LDL-C; cardiovascular risk; Cholesterol Treatment Trialists' Collaboration; meta-regression analysis; CORONARY-HEART-DISEASE; HIGH-DOSE ATORVASTATIN; PRIMARY PREVENTION; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; OLDER PATIENTS; END-POINTS; PRAVASTATIN; EVENTS; AVERAGE;
D O I
10.1016/j.clinthera.2009.02.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In 2005, the Cholesterol Treatment Trialists' Collaboration (CTTC) quantified the relationship between reduction in low-density lipoprotein cholesterol (LDL-C) achieved by statin treatment and reduction in cardiovascular risk. Since this publication, several large statin trials have been reported. Objective: The objective of our analysis was to extend the CTTC results by including active-controlled trials and other trials published since 2005. Methods: A literature search in English (1966-December 2008) Was undertaken of MEDLINE, EMBASE, Derwent drug file databases, and the Cochrane library using standard MESH terms (cardiovascular disease, death, fatal outcome, pravastatin, simvastatin, atorvastatin, rosuvastatin, fluvastatin, lovastatin, and hydroxymethylglutaryl coenzyme A reductase inhibitors) to identify randomized trials of statins (placebo controlled, active controlled, or usual care) that reported clinical outcomes, enrolled >1000 Subjects, and followed them up for >= 1 year. Random effects meta-regression was used to analyze the relationship between absolute changes in LDL-C and risk for cardiovascular events. Results: Twenty-five trials were included in a primary analysis involving 155,613 subjects, 6321. vascular deaths, 23,791. major vascular events, 11,357 major coronary events, and 4717 strokes. For every 25-mg/dL (0.65-mmol/L) reduction in LDL-C, the relative risk (95% CI) for various cardiovascular outcomes was as follows: vascular mortality, 0.89 (0.87-0.92); major vascular events, 0.86 (0.84-0.88); major coronary events, 0.84 (0.82-0.86); and stroke, 0.90 (0.86-0.94). Conclusions: Based on meta-regression analysis of these trials, there was a significant positive relationship between reduction in LDL-C and reduction in the risk for major cardiovascular events. These results support and extend the findings of the CTTC. (Clin Ther. 2009;31:236-244) (C) 2009 Excerpta Medica Inc.
引用
收藏
页码:236 / 244
页数:9
相关论文
共 35 条
[1]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[2]  
[Anonymous], 2002, JAMA, V288, P2998
[3]  
[Anonymous], 2000, ITAL HEART J
[4]   Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228
[5]  
Baigent C, 2008, LANCET, V371, P2084
[6]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[7]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[8]  
Cannon CP, 2006, NEW ENGL J MED, V354, P778
[9]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3